the FitnessRx-from-BPI threads keep landing on turnaround time as the headline, and i get why, waiting a week on Mintmeds while another vendor has you a delivery slot by 3:30pm the same day is a real difference in lived experience. but speed and what’s in the vial are two separate questions, and i wanted to put down what the actual analysis work says, because it’s more specific than the forum framing. the independent testing i’ve read on compounded GLP-1 product (the batches pulled and run by third parties, not the manufacturer’s own COA) found two things worth separating. one is potency variance, vials coming in meaningfully under or over the stated label, which is a fill and formulation question. the other is identity, a few samples that weren’t the expected molecule or carried impurities above what you’d want. those are different failure modes and a fast delivery date speaks to neither. here’s the part that doesn’t make page one. when people say “it comes from BPI,” what they’re describing is the upstream API origin. the document that would actually answer your question is finished-vial release data, sterility, endotoxin, potency confirmation on the vial that shipped to you, not the API the powder started as. a solid COA on the raw material and essentially nothing on the finished product is the most common gap i see, and the analyses that found variance were testing the finished product precisely because that’s the layer nobody publishes. so the question i’d actually ask FitnessRx, before the delivery window even matters: can you point me to the potency and sterility data on this batch number, the one in my box. not a policy page saying they test. the specific result. i’m not making a clinical call on whether any of these sources is fine to use, that’s genuinely above my lane. but the speed impressed everyone and the verification got skipped, and the literature suggests verification is the variable that actually moved between batches. fast is nice. fast tells you about their logistics, not their fill.